Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases. It has a poor prognosis compared to multiple myeloma, with a median survival of 8–12 months. The results of conventional therapy are disappointing though autologous stem cell transplantation appears to improve survival.
|
Cancer Treatment Today
228 Park Ave S #70464
New York, NY 10003-1502
info@cancertreatmenttoday.org
Tel - 212-372-7263